As Part of Its Request for Offer for a Low-Cost Male UAV, DGA (French Defense Procurement Agency) Has Notified FLY-R of Its First Contract Based on the R2-600 Rhomboid UAV
LE BOURGET, France--(BUSINESS WIRE)--FLY-R, the French company specializing in the design and construction of rhomboid-wing UAVs, has been notified of a contract within the framework of a request for offer launched by DGA to develop the largest model of the FLY-R range, the R2-600.
Thanks to its specific aerodynamics, the rhomboid wing, a type of shape similar to a lozenge, with no vertical surface, allows speed ranges and maneuverability far superior to other sail shapes. For similar wingspan, a rhomboid-wing aircraft can double the performance in terms of speed, flight time and payload carried. Nevertheless, no system based on rhomboid wing could be operationally developed because of its complexity. But progress recently realized in the fields of aerodynamics, computational code, new materials, equipment and propulsion, have allowed the success of FLY-R innovative approach.
FLY-R is developing a complete range of UAVs with wingspans of 1.20 m, 1.50 m, 2.40 m and 6.00 m. The R2-600, the object of DGA's request for offer, is a hybrid-powered medium-altitude long-endurance (MALE) UAV with a maximum take-off weight (MTOW) of 1,700 kg, capable of flying up to 45,000 feet (around 15,000 meters) for missions of more than 20 hours.
The R2-600 is particularly well-suited to military missions: surveillance of vast areas, operations in hostile territory, offensive missions thanks to its weapons-carrying capacity, and the possibility of remote launch from a deployable infrastructure, while maintaining a very moderate cost to facilitate mass deployment.
According to the terms of this request for offer, FLY-R must demonstrate the R2-600's operational capabilities in flight before the end of 2026. The fact that FLY-R has been selected for this request for offer illustrates the company's success in the design and development of these new types of aircraft, thanks to high-quality R&D and exemplary cooperation with ONERA (French National Aeronautical Laboratory) and the Duqueine group, which specializes in the design and manufacture of parts and sub-assemblies in high-performance composite materials, notably for the aeronautics sector.
As part of its international development strategy, FLY-R is in discussions with defense contractors in the European Union and Middle East countries.
« The current geostrategic context shows that drones have become essential components of military operations. FLY-R has been working for several years on rhomboid-wing UAVs, which are complex to build. The expertise of our teams has enabled us to take a major technological step forward by developing a complete range of these unmanned vehicles, including the R2-600 which, if it meets the requirements of the request for offer, will complete the French air arsenal with an easy-to-use and costeffective machine. »
Laurent COLLET-BILLON, CEO of FLY-R
« Being selected for this request for offer is a source of pride for our teams, and the achievement of years of research, development and testing. We would like to thank DGA for its confidence, as well as ONERA and the Duqueine Group for the quality of our partnership. »
Rémi ALBERT, Deputy CEO of FLY-R
« The Duqueine Group is delighted to contribute to the manufacture of the first large-scale rhomboid UAV designed by FLY-R, which represents a remarkable innovation for aeronautics and MALE missions in particular. »
Gilles DUQUEINE, President of the Duqueine Group
« FLY-R has proven expertise in rhomboid wing systems and a high degree of maturity in complex aeronautical systems. Rhomboid wing systems have demonstrated excellent aerodynamic and structural performance, with unique flying qualities and the ability to perform original maneuvers. The implementation of the rhomboid configuration in a MALE context seems to us to be highly relevant. »
Franck LEFÈVRE, General Technical Director of ONERA
FLY-R is chaired by Éric Thieulin, and its executive committee includes Laurent Collet-Billon, CEO Strategy & Development; Rémi Albert, Deputy CEO Operations & Business; François Varigas, CTO.
About FLY-R
FLY-R has been Founded in 2013 by François Varigas and Rémi Albert, civil and military engineers. The company has developed a full range of remarkably efficient rhomboid drones from 1.20 to 6.00 meters wingspan, used in civil (surveillance of industrial complexes, medical assistance, combating illegal trafficking...) and military applications (target detection, air-to-ground strikes, operations in hostile territory, air defense, air combat...). Since 2019, FLY-R has forged an in-depth partnership with the Office national d'Etudes et de Recherches Aérospatiales (ONERA). In 2023, FLY-R was awarded the 1st Innovation Prize by the French Ministry of Defense and the Special Forces at SOFINS, the Special Forces Defense and Armament Exhibition, flyr-uas.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Dr. Kaye, a current member of NervGen's Board of Directors and Chair of the Science Committee since 2020, brings highly relevant and extensive experience in central nervous system (CNS) therapeutic development, regulatory strategy, and medical affairs to the NervGen team. The expanded engagement follows the company's announcement of positive topline results in the chronic cohort of the Phase 1b/2a clinical trial evaluating NVG-291 in individuals with cervical spinal cord injury. "We are very pleased to welcome Dr. Kaye in his expanded capacity as a medical advisor to the company," said Mike Kelly, NervGen's President & CEO. "In addition to his close history and contributions to the NVG-291 program, he brings extensive industry and CNS development expertise focused on clinical and regulatory strategy. Dr. Kaye has highly relevant experience and is well positioned to assist the team in analyzing the complete chronic cohort data and help chart the next phase of NVG-291's clinical and regulatory pathway, which includes assisting in preparations for our anticipated meeting with the U.S. Food and Drug Administration (FDA) in the second half of this year." As a NervGen Board member and Science Committee Chair, Dr. Kaye has served as an advisor to the NVG-291 program since its early clinical development. He previously served as chief medical officer of multiple biopharmaceutical companies, including most recently at Longboard Pharmaceuticals Inc., where he helped guide CNS development programs through a $2.6 billion acquisition by H. Lundbeck A/S. His expertise spans the areas of neurology, psychiatry, immunology, and infectious disease, and includes oversight of clinical operations, regulatory affairs, and medical strategy. Dr. Kaye earned his MD, MPH, and BS degrees from George Washington University and completed a Research Fellowship at Harvard Medical School. About NVG-291 NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology is licensed from Case Western Reserve University and is based on academic studies that demonstrated the preclinical efficacy of NVG-291-R, the rodent prototype of NVG-291, in animal models of spinal cord injury. These studies implicated several potential molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. The implicated mechanisms include the promotion of neuronal sprouting, or plasticity, remyelination, and promotion of a non-inflammatory phenotype in the microglial cells. NervGen has received Fast Track designation from the FDA for NVG-291 in individuals with spinal cord injury. About NervGen NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury. Topline data from the chronic cohort (1-10 years post-injury) of this trial showed that NVG-291 met its primary endpoint and demonstrated promising changes in a secondary endpoint assessing hand function. Enrollment in the subacute cohort (20-90 days post-injury) of the trial continues, and more information about participation in the subacute study is available at In addition, the company has initiated preclinical test of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information about NervGen, visit and follow NervGen on X and LinkedIn for the latest news on the company. Contacts Huitt Tracey, Investor Relationshtracey@ Bill Adams, Chief Financial Officerinfo@ Christy CurranSam Brown Healthcare Communicationschristycurran@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the strategic guidance to be provided by the chief medical advisor; the anticipated meeting with the FDA; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and timing of data readout and study design of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; the future development plans and benefits of NVG-291; the development plans and prospective target indications for NVG-300; and the creation of neuroreparative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
40 minutes ago
- Business Wire
DocGo Announces Upcoming Participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) ('DocGo' or the 'Company'), a leading provider of technology-enabled mobile health and medical transportation services, today announced that the Company will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025 on June 24 and 25, 2025. Representing the Company, CEO Lee Bienstock will deliver a presentation at 1:00 ET on Tuesday, June 24, followed by one-on-one meetings with investors on Wednesday, June 25. A webcast of the event will be available on the investor relations section of DocGo's website at iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between company management teams and pre-qualified investors on Day 2. For more information about the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025, or to register and schedule a one-on-one meeting with DocGo, please visit the conference website at: About DocGo DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for municipalities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote advanced practice provider, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit
Yahoo
40 minutes ago
- Yahoo
Language Learning Market to Reach USD 227 Billion by 2035, Says Meticulous Research®
Market Growth Driven by Digital Transformation, AI-Powered Platforms, Government Multilingualism Policies, Immigration Trends, and Corporate Training Demand REDDING, Calif., June 18, 2025 /PRNewswire/ -- The global language learning market was valued at USD 64.3 billion in 2024 and is projected to reach USD 227.0 billion by 2035, growing from an estimated USD 69.9 billion in 2025, at a CAGR of 12.5% during the forecast period of 2025-2035, according to a new market research report titled "Language Learning Market Size, Share, Forecast, & Trends Analysis by Age Group (<18 years, 18-20 years, 21-30 years, 31-40 years, >40 years), Language (English, Mandarin, Spanish, French, German, Italian, Japanese) End User (B2C, B2B)—Global Forecast to 2035", published by Meticulous Research®. The language learning market is experiencing unprecedented transformation as globalization, digital innovation, and changing workforce requirements create massive demand for multilingual skills across education, business, and personal development sectors. Download FREE sample report: What's Driving 12.5% Annual Growth? Digital Transformation Revolutionizes Learning Technology is fundamentally reshaping how people acquire languages through AI-powered applications, gamification, and virtual classrooms. Platforms like Duolingo and Babbel leverage adaptive algorithms for personalized lessons, while speech recognition technology enhances pronunciation practice. Gamified elements including rewards and leaderboards boost engagement rates by up to 70% compared to traditional methods. Government Policies Mandate Multilingual Education Governments worldwide are implementing comprehensive language education policies to foster global competitiveness. China emphasizes English proficiency for economic development, while the EU promotes regional language diversity. Standardized tests like TOEFL and IELTS drive demand for specialized preparation services, with public schools increasingly incorporating bilingual programs. Immigration and Travel Create Practical Demand Post-pandemic travel resurgence and continued global migration fuel practical language learning needs. Immigrants require host-country language skills for employment and social integration, while travelers seek conversational abilities for popular destinations. Language apps now offer specialized travel courses covering dining, transportation, and emergency communication. Corporate Training Expands Rapidly Multinational corporations increasingly invest in employee language training to enhance international business communication. The B2B segment is expected to account for over 56% market share in 2025, driven by industry-specific language requirements and cross-border collaboration needs. Market Segmentation Reveals Key Trends Younger Learners Lead Adoption The under-18 segment dominates with over 43% market share in 2025, benefiting from enhanced cognitive development, improved academic performance, and early preparation for global career opportunities. However, the 18-20 age group shows highest growth rates as students prepare for international education and employment. English Maintains Global Dominance English language learning holds over 67% market share, supported by globalization trends and universal business communication requirements. However, Mandarin exhibits fastest growth, leveraging China's economic influence and 1.117 billion global speakers. B2B Segment Drives Revenue Growth Business-to-business applications lead market share at 56%, driven by corporate training programs and professional development initiatives. The B2C segment demonstrates higher growth potential during the forecast period, supported by individual learners seeking career advancement and cultural enrichment. Request customized analysis: Regional Analysis: Asia-Pacific Leads Global Market Asia-Pacific Dominance Expected Asia-Pacific is projected to account for over 49.2% of the global market in 2025 and register the highest CAGR during the forecast period. Growth drivers include multinational company expansion, government education initiatives, rapidly developing economies, and increased internet penetration from rising disposable incomes. Emerging Markets Offer Untapped Potential Countries including India, Indonesia, Vietnam in Asia, and growing markets across Africa and Latin America represent significant expansion opportunities. These regions require localized approaches with culturally relevant content, affordable pricing models, and mobile-optimized platforms addressing infrastructure limitations. Technology Innovation Creates New Opportunities AI and Personalization Lead Innovation Artificial intelligence enables hyper-personalized learning experiences through adaptive algorithms adjusting difficulty and content based on individual progress. Real-time pronunciation coaching, conversational chatbots powered by large language models, and predictive analytics optimize learning outcomes. Mobile-First Platforms Dominate Smartphone penetration drives mobile-first platform adoption, enabling flexible, on-demand learning that fits busy lifestyles. Microlearning principles and offline capabilities address connectivity challenges in emerging markets. Gamification Enhances Engagement Achievement systems, social competitions, and immersive storylines transform language acquisition from academic obligation into engaging experiences. These elements significantly improve retention rates and sustained user engagement. Recent Market Developments April 2025: Duolingo launched its largest-ever course expansion, leveraging AI to add 10+ new languages including Zulu and Xhosa, while introducing adaptive exercises and real-time feedback systems. February 2025: Babel announced strategic collaboration with OpenAI to enhance Generative Artificial Intelligence capabilities for digital transformation in language learning. Market Opportunities and Growth Outlook Specialized Training Programs Business English, technical vocabulary, and cultural context training represent high-value market segments with premium pricing potential. Industry-specific programs for healthcare, aviation, and technology sectors address specialized communication requirements. Immersive Technology Integration Virtual and augmented reality applications create authentic learning environments for conversational practice and cultural immersion without geographic constraints. These technologies address limitations of traditional classroom instruction. Corporate Partnership Expansion Strategic partnerships with educational institutions, government agencies, and multinational corporations provide distribution channels and market credibility for platform expansion. Competitive Landscape Leading market players include Cambridge University Press (U.K.), New Oriental Education & Technology Group Inc. (China), Houghton Mifflin Harcourt Company (U.S.), McGraw-Hill Education Inc. (U.S.), Duolingo Inc. (U.S.), Berlitz Corporation (U.S.), Busuu Online S.L. (Spain), Babbel GmbH (Germany), and emerging technology-focused platforms. Competition intensifies between established educational publishers adapting digital strategies and technology-native companies leveraging AI, gamification, and mobile-first design to capture digital-native learners seeking flexible, engaging educational experiences. Purchase complete report: About Meticulous Research® Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence, strategic insights, and consulting services to serve clients across 11 major industries globally. Meticulous Research® offers comprehensive market research reports, custom research, and consulting services. Our research studies help clients make informed business decisions and understand emerging business trends and opportunities. The company's expertise spans across various domains, enabling it to provide accurate insights and strategic recommendations to its clients. Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email: sales@ Source: Logo: View original content: SOURCE Meticulous Market Research Pvt. Ltd. Sign in to access your portfolio
